Development and Optimization of Intelligent Polymeric Nexus for Controlled Drug Delivery

Le résumé fourni par la source

A novel acyclovir (ACV)-loaded nexus was synthesized by grafting methacrylic acid (MAA) onto β-CD and pectin using N, N methylene bis-acrylamide (MBA) as a crosslinker. A graft co-polymerization reaction was adopted for grafting monomer (MAA) onto β-CD and pectin backbone. The influence of substrate concentrations (β-CD, pectin, MAA, and MBA) on swelling and ACV release was studied. It was observed that as the ratio of β-CD increases, swelling of the nexus increases from 82 ± 0.34 to 92 ± 0.34 in pH 7.4 and from 7.45 ± 0.24 to 9.34 ± 0.34 in pH 1.2. Moreover, as the pectin concentration increases, the swelling increases from 76 ± .34 to 88 ± 0.34 in pH 7.4 and from 7.34 ± 0.34 to 10.24 ± 0.56 in pH 1.2. Furthermore, with increases in the MAA concentration, swelling increases from 76.56 ± 0.34 to 96.45 ± 0.35 in pH 7.4 and from 8.34 ± 0.34 to 10.87 ± 0.45 in pH 1.2. However, with an increment in MBA concentration, swelling decreases, i.e. from 97 ± 0.45 to 70.45 ± 0.45 in pH 7.4 and from 9.18 ± 0.34 to 6.1 ± 0.35 in pH 1.2. A similar trend was observed for drug release. All formulations BP1 to BP12 depicted drug release between 69.93% and 95.1%. FTIR studies elucidated successful grafting. Thermal analysis was used to predict the stability of the ACV within the nexus. SEM was carried out to elucidate the conformation, configuration and topology of the ACV entrapped nexus. Hence, the optimized nexus (BP-9) serves as a nontoxic, bio-compatible carrier for controlled delivery of acyclovir.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.